

Wild-type p53 overexpression in *NPM1*-mutated acute myeloid leukemia: potential implications for disease biology and therapy response

Authors

Paul D. Barone,^{1*} Siarhei Dzedzik,^{2*} Ashley S. Kleinman,^{3-5*} Christopher R. Chin,^{4,6,7} Cem Meydan,^{3,4,6} Itzel Valencia,⁸ Mayumi Sugita,⁹ Monica L. Guzman,⁹ Joshua A. Fein,⁹ Justin D. Kaner,⁹ Pinkal Desai,⁹ Gail J. Roboz,⁹ Ari M. Melnick,⁹ Christopher E. Mason^{3,4,6,7,10,11} and Sanjay S. Patel^{1,8}

¹Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, NY; ²Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, NY; ³Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY; ⁴The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY; ⁵Department of Earth, Atmospheric, and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, MA; ⁶Department of Medicine, Weill Cornell Medicine, New York, NY; ⁷Tri-Institutional Computational Biology and Medicine Program, Weill Cornell Medicine, New York, NY; ⁸Multiparametric In Situ Imaging (MISI) Laboratory, Department of

Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY; ⁹Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY; ¹⁰The Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY and ¹¹WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, USA

**PDB, SD and ASK contributed equally as first authors.*

Correspondence:

S.S. PATEL - sap9151@med.cornell.edu

<https://doi.org/10.3324/haematol.2025.288054>

Received: April 28, 2025.

Accepted: September 2, 2025.




Early view: September 11, 2025.

©2026 Ferrata Storti Foundation



Published under a CC BY-NC license 

Group	Number of cases per group	Minimum # of cells	Maximum # of cells	Median
NPM1-mutated	33	1869	31151	10528
TP53-mutated	5	3379	23273	8598
NPM1/TP53-WT	7	2747	22935	8703
All cases	45	1869	31151	8957

Supplemental Figure 1. Total nucleated cells analyzed by MxIF across all cases/groups.



Supplemental Figure 2. A. No correlation between frequency of p53-positive and Ki67-positive cells in cases *NPM1*-AML. B. Representative example of an *NPM1*-AML case stained with antibodies to mutant NPM1 (blue), p53 (green), and MDM2 (red). The MDM2 signal is predominantly nuclear; evidence of cytoplasmic (i.e. blue/green overlap) dislocation of MDM2 is inconspicuous. C. Frequency of p53 expression among *NPM1*-mutated cells does not differ based on presence or absence of co-mutation in *IDH1/2* (left), *DNMT3A* (center), or *FLT3-ITD* (right).



Supplemental Figure 3. Within each case of *NPM1*-AML analyzed by MxIF, a greater proportion of *NPM1*-mutated cells are p53-positive (left) and have higher nuclear p53 MFI (right), compared to *NPM1*-WT cells. Aggregate data demonstrating the statistical significance of the differences between *NPM1*-mutated cells and *NPM1*-WT cells are shown in Figure 2 of the main paper.